VRTX

As of 2026-10-26, VRTX scores 53out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. VRTX trades at $517.49, 14% above the band ceiling.

VRTX scores 53 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 53. Its strongest factor is quality at 61 (solid), where earnings quality and balance-sheet strength stand out, followed by value at 58. The weakest is volume at 43, where volume gives little confirmation. Among Healthcare stocks it ranks in roughly the top 37% of the Healthcare names the model scores.

On valuation, VRTX is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 54. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on VRTX, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where VRTX sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for VRTX runs $344.67–$454.02. Current price $517.49 sits 14% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.